

# Endoscopy International Open

## Antibiotic Prophylaxis in Digestive Endoscopy – Guidelines from the French Society of Digestive Endoscopy

David Karsenti, Rodica Gincul, Arthur Belle, Ariane Vienne, Emmanuel Weiss, Geoffroy Vanbiervliet, Olivier Gronier.

Affiliations below.

DOI: 10.1055/a-2415-9414

Please cite this article as: Karsenti D, Gincul R, Belle A et al. Antibiotic Prophylaxis in Digestive Endoscopy – Guidelines from the French Society of Digestive Endoscopy. Endoscopy International Open 2024. doi: 10.1055/a-2415-9414

**Conflict of Interest:** Competing interests in relation to the guidelines: None declared.

**Other competing interest:**

David Karsenti, MD: Consultant for OLYMPUS, COVIDEN and NORGINE; Support for attending meetings from ALFASIGMA, COOK and FUJIFILM

Rodica Gincul, MD: Consultant for OLYMPUS; Honoraria for lectures from OLYMPUS; Support for attending meetings from CELTRION, ABBVIE

Arthur Belle, MD: Consultant for BOSTON SCIENTIFIC; Support for attending meeting from MAYOLI

Geoffroy Vanbiervliet, MD-PhD: Consultant for BOSTON SCIENTIFIC and AMBU; Honoraria for lectures, presentations and speeches from PENTAX, FUJIFILM, TILLOTS and NORGINE

Olivier Gronier, MD: Support for attending meetings from Dr FALK

### Abstract:

Digestive endoscopy is a highly dynamic medical discipline, with the recent adoption of new endoscopic procedures. However, comprehensive guidelines on the role of antibiotic prophylaxis in these new procedures have been lacking for many years. The Guidelines Commission of the French Society of Digestive Endoscopy (SFED) convened in 2023 to establish guidelines on antibiotic prophylaxis in digestive endoscopy for all digestive endoscopic procedures, based on literature data up to September 1, 2023. This article summarizes these new guidelines and describes the literature review that fed into them.

### Corresponding Author:

Dr. David Karsenti, Clinique de Bercy, Digestive Endoscopy Unit, 9 quai de Bercy, 94220 CHARENTON LE PONT, France, karsenti.paris@gmail.com

### Affiliations:

David Karsenti, Clinique de Bercy, Digestive Endoscopy Unit, CHARENTON LE PONT, France

David Karsenti, Centre d'Explorations Digestives, Gastroenterology, PARIS, France

Rodica Gincul, Jean Mermoz Private Hospital, Lyon, France

[...]

Olivier Gronier, Clinique Sainte Barbe, 67000, Strasbourg, French Polynesia

## **Antibiotic prophylaxis in digestive endoscopy - Guidelines from the French Society of Digestive Endoscopy**

David Karsenti<sup>1-2</sup>, Rodica Gincul<sup>3</sup>, Arthur Belle<sup>4</sup>, Ariane Vienne<sup>5</sup>, Emmanuel Weiss<sup>6</sup>, Geoffroy Vanbiervliet<sup>7</sup>, Olivier Gronier<sup>8</sup>

Recommendation commissioned by the French Society of Digestive Endoscopy (SFED)

<sup>1</sup> Clinique Paris-Bercy, Pôle Digestif Paris-Bercy, Charenton-le-Pont, France

<sup>2</sup> Centre d'Explorations Digestives, 50 rue de Rennes, Paris, France

<sup>3</sup> Hôpital privé Jean Mermoz, Service de Gastroentérologie, Lyon, France

<sup>4</sup> Hôpital Cochin, AP-HP Centre, Service de Gastro-entérologie et Oncologie Digestive, Paris, France

<sup>5</sup> Hôpital privé, Service d'Endoscopie Digestive, Antony, France

<sup>6</sup> AP-HP.Nord, Hôpital Beaujon, Service d'Anesthésie-Réanimation, Clichy, SFAR representative, France

<sup>7</sup> CHU de Nice, Hôpital L'Archet 2, Pôle DIGi-TUNED, Endoscopie Digestive, Nice, France

<sup>8</sup> CHU de Strasbourg, Service d'Endoscopie Digestive, Strasbourg, France

Corresponding author: D. Karsenti  
karsenti.paris@gmail.com

### **Abstract**

Digestive endoscopy is a highly dynamic medical discipline, with the recent adoption of new endoscopic procedures. However, comprehensive guidelines on the role of antibiotic prophylaxis in these new procedures have been lacking for many years. The Guidelines Commission of the French Society of Digestive Endoscopy (SFED) convened in 2023 to establish guidelines on antibiotic prophylaxis in digestive endoscopy for all digestive endoscopic procedures, based on literature data up to September 1, 2023. This article summarizes these new guidelines and describes the literature review that fed into them.

# **Antibiotic prophylaxis in digestive endoscopy**

## **A/ Introduction**

Antibiotic prophylaxis (AP) involves the administration of one or more antibiotic molecules to prevent the development of a specific infection under determined circumstances. It differs from curative antibiotic therapy, which is intended to treat an already established infection.

In digestive endoscopy, the objective of AP is to prevent the occurrence of local and/or general infectious complications following an endoscopic procedure.

Although these types of complications remain rare in endoscopy, the prevalence of bacteremia after certain endoscopic procedures can be high.

Transient bacteremia frequently occurs during our daily activities, at rates and frequencies higher than those associated with endoscopic procedures. For example, tooth brushing is associated with bacteremia rates between 20% and 68%, the simple physiological activity of chewing with rates between 7% and 51%, and the use of a toothpick with rates between 20% and 40% [1].

The bacterial infectious risk secondary to an endoscopic procedure must also be balanced against the side effects of AP, including allergic reactions (of varying severity) and the potential induction of antibiotic resistance.

Therefore, determining the risk situations in which AP is recommended for a limited number of patients is essential.

These types of situations depend on two factors, which must be independently analyzed in order to assess the indication:

- the patient-related infectious risk (consideration of comorbidities: cardiovascular context, immunosuppression, peritoneal dialysis, cirrhosis, etc.);
- the procedure-related risk (consideration of the bacterial infectious risk induced by the examination).

## **B/ Methods**

The French Society of Digestive Endoscopy (SFED) and the French Society of Anesthesia and Intensive Care Medicine (SFAR) were responsible for developing these guidelines, and invited D.K. to be the Chair of the guidelines working group in November 2021. D.K. selected a working group from the SFED, including the listed authors, who were broadly representative in terms of their wide range of diagnostic and therapeutic GI procedures expertise and level of clinical experience and background, and E.W. selected a working group from the SFAR. The first meeting of the working group was held in January 2022, where the overall aims of the project were defined and the methodology was agreed. Specific questions were developed using the Population, Intervention, Comparator, Outcome (PICO) format where possible:

- general principles;
- therapeutic GI procedures;
- diagnostic and therapeutic EUS procedures;
- retrograde cholangiopancreatography procedures.

The working group was organized into four sub-task forces covering the above areas, with one group member nominated as the lead of each sub-group. Each area was the subject of a systematic literature review. A literature search of PubMed/MEDLINE, the Cochrane Library, and Embase was performed by the authors, focused on relevant randomized controlled trials (RCTs) and meta-analyses published up to June 2023. Retrospective analyses and case series were also included if the area concerned was not covered in prospective studies. Statements were drafted based on the evidence collected and evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework [2]. When a paucity of evidence was noted, the groups relied on expert opinion to develop statements.

Several task force meetings were held from January 2022 to November 2023, where the statements were discussed and modified based on the feedback of the members, in order to improve their acceptability.

Each sub-group developed draft proposals that were discussed. After agreement on a final version, the manuscript was reviewed by all members of the guidelines committee. This final version was validated by the SFED and SFAR before submission to the journal *Endoscopy International Open* for publication. All authors agreed on the final revised manuscript.

## **C/ Patient-related risk**

### **a/ Prevention of infective endocarditis**

The European Society of Cardiology (ESC) has defined situations at risk for endocarditis that would require the use of AP [3]. These recommendations have been endorsed by the French Infectious Diseases Society (SPLIF), the French Society of Cardiology (SFC), and the French Society of Anesthesia and Intensive Care Medicine (SFAR).

AP is only recommended for patients with a cardiac condition at high risk for endocarditis:

- patients with prosthetic valves or prosthetic material used for valve repair;
- patients with a history of infective endocarditis;
- patients with unoperated cyanogenic congenital heart disease, residual leakage, or surgical shunt placement;
- patients with congenital heart disease with prosthetic repair, placed surgically or percutaneously, up to 6 months after placement;
- patients with residual leakage at the site of prosthetic material placement, placed surgically or percutaneously.

For these patients, the only interventions at risk of bacteremia that could lead to endocarditis are those involving dental manipulations of the gums or peri-apical region and perforation of the oral mucosa.

For other procedures, including diagnostic endoscopies (esophagogastroduodenoscopy [EGD] and colonoscopy), AP is no longer indicated.

Furthermore, there are no reported cases of vascular graft infection related to gastrointestinal endoscopic procedures.

Therefore, AP is not recommended before diagnostic gastrointestinal endoscopic procedures in a patient with non-valvular synthetic vascular materials, such as

pacemakers, defibrillators, coronary or peripheral vascular stents, and inferior vena cava filters [3].

## **b/ Comorbidity-related risk**

Numerous factors may be considered to be potentially or definitely associated with the occurrence of a surgical site infection. As highlighted by the SFAR in its latest recommendations, the presence of such factors does not necessarily mandate systematic AP in situations where such treatment is not recommended [4].

Only studies providing significant evidence on the administration of AP in the presence of a risk factor would be able to validate or negate the usefulness of AP in such a situation. To date, no such studies are available.

Thus, the use of AP for any endoscopy with a risk of bacteremia (especially for polypectomy within 6 months following prosthetic surgery) was recommended by the American Association of Orthopedic Surgeons (AAOS) in the late 2010s for patients with orthopedic prostheses, following a few reported cases of pyogenic arthritis after endoscopy [5]. However, the American Society for Gastrointestinal Endoscopy (ASGE) did not endorse this indication in its 2015 guidelines, due to a lack of reliable data [6].

Nevertheless, it may be worth considering AP in certain specific situations, on a case-by-case basis and taking into account the procedure-related risk. Some indications are discussed by the SFAR in its 2018 recommendations [4]:

- For patients with severe neutropenia (absolute neutrophil count < 0.5 G/L) or advanced hematologic malignancy, there is an increased risk of bacteremia and septicemia after gastrointestinal endoscopy [7]. However, the benefit of AP in this specific population has not been studied. The same applies to patients who have undergone radiotherapy, immunocompromised patients with a normal neutrophil count (organ transplant recipients, HIV-positive individuals), patients who are undergoing chemotherapy or corticosteroid therapy, patients with uncontrolled diabetes, very elderly patients, and obese or malnourished patients. The decision to use AP in these situations should be made on a case-by-case basis. Furthermore, although these patients are at a higher risk of surgical site infection, they will have infections caused by the “target bacteria” of usual AP, and no modification of the proposed protocols seems justified in these patients.
- Peritoneal dialysis: patients with end-stage renal failure undergoing peritoneal dialysis have higher rates of infection than those treated with hemodialysis. Since 2005, the International Society for Peritoneal Dialysis (ISPD) has suggested in its recommendations that AP be administered before lower endoscopy [8, 9]. The ASGE adopted similar suggestions in its 2015 guidelines [10]. However, there is limited data, including no randomized controlled trials, to support these suggestions. A multicenter retrospective study showed that out of 236 patients who underwent colonoscopy, 9 (3.8%) developed peritonitis [11]. Polypectomy or mucosectomy rates were significantly higher in the peritonitis group vs. the non-peritonitis group (66.7% vs. 23.4%;  $P = 0.009$ ). Moreover, among the 65 patients who received AP, none developed peritonitis and, conversely, none of the patients who developed peritonitis had received AP ( $P = 0.067$ ). Thus, although the decision to use AP must also consider the associated risks, such as *Clostridium difficile* infections and the development of multi-resistant organisms, the possibility of using AP should be systematically discussed. Lastly, a more recent retrospective study involving 1,316 endoscopic procedures in 570 peritoneal dialysis patients, reporting a peritonitis rate of 4.2% after colonoscopy, noted no reduction in the risk of peritonitis with AP



**[12].** However, polypectomy was associated with an increased risk of post-colonoscopy peritonitis (OR = 6.5; 95% CI 1.6-25.9) in this study.

## **D/ Procedure-related risk (see Table 1)**

This non-exhaustive list aims to provide an overview of current knowledge regarding infectious risk and the assessment of AP in specific conditions.

In cases of high risk of endocarditis, a confirmed infection and/or a high risk of bacteremia are required to consider AP.

### **a/ Endoscopic procedures with a low risk of infection**

#### **EGD with or without biopsy**

Although EGD with or without biopsy is associated with a bacteremia mean rate of 4.4%, bacteremia is generally of short duration (< 30 minutes) and not associated with infectious adverse events **[13]**.

#### **Therapeutic EGD procedures (endoscopic mucosal resection [EMR], endoscopic submucosal dissection [ESD] and per-oral myotomy)**

The use of AP after gastric ESD is controversial. A prospective study involving 103 patients who underwent gastric ESD without AP showed that the incidence of bacteremia at 24 hours did not significantly differ between a group of patients with a procedure complicated by perforation (N = 40) and a group without perforation (N = 63) (2.5% vs. 3.2%; P > 0.05). No patient in this study developed septicemia. The authors concluded that, even in cases of perforation (treated endoscopically during the procedure), AP was not necessary **[14]**.

Similarly, although a high incidence of bacteremia after esophageal endoscopic procedures has been reported, the incidence of bacteremia associated with esophageal ESD remains unknown. A recent prospective study involving 101 patients who underwent esophageal ESD showed bacteremia in six patients (6%) immediately after ESD, and only one patient had a positive blood culture the next morning. None of these patients developed an infectious syndrome. Moreover, among the 10 patients who developed a post-ESD fever of  $\geq 38$  °C, none had a positive blood culture. Overall, none of the patients in this study required antibiotics after esophageal ESD **[15]**. The authors emphasized that post-ESD fever is not frequently associated with the presence of bacteremia, making routine AP in patients undergoing esophageal ESD appear unnecessary.

Regarding the endoscopic treatment of achalasia by per-oral endoscopic myotomy (POEM), a recent randomized controlled study involving 124 patients compared the efficacy of a single dose of AP with prolonged AP. The study compared a group receiving a prophylactic single dose of 2g of intravenous cefazolin to a group receiving the same initial dose followed by 2g of intravenous cefazolin three times a day, further followed by oral amoxicillin-clavulanic acid. No significant differences were found in terms of the occurrence of clinical signs, bacteremia, or infectious or inflammatory syndrome **[16]**. A case-control study of 226 patients showed no impact of AP on the occurrence of post-POEM infectious complications, and even a higher risk of adverse events (P = 0.003) **[17]**.

#### **Diagnostic colonoscopy**

Colonoscopy-related bacteremia rates are low, even during certain procedures such as colonic stent insertion, where bacteremia is reported in only 6.3% of cases. The low rates seem to be linked to the duration of the procedure, with the bacteremia remaining entirely asymptomatic, suggesting that AP is not necessary [18].

### **Therapeutic colonoscopy (EMR and ESD)**

A recent meta-analysis, including three randomized trials and one retrospective study and involving 850 patients, assessed the utility of AP in patients undergoing endoscopic mucosal or submucosal resections (548/850 patients treated with antibiotics). The overall incidence rate of post-operative adverse events was 2.4% in the treatment group vs. 19.9% in the control group. The analysis showed an 83% reduction in post-operative events in the antibiotic treatment group (relative risk [RR] 0.181; 95% CI 0.100-0.326;  $P < 0.001$ ). The authors suggested that AP may be useful but highlighted the low level of evidence in their meta-analysis, ultimately concluding that additional large-sample, multicenter randomized controlled studies are needed, especially to evaluate the benefit of AP in specific subgroups such as extensive ESD [19].

A recent prospective multicenter randomized study, involving 432 patients (216 in the AP group vs. 216 in the control group) in 21 centers in Japan, evaluated the impact of AP in colorectal ESD. After the exclusion of 52 patients, 192 in the AP group and 188 in the control group were analyzed. A post-resection syndrome occurred in 9 out of 192 patients (4.7%) in the AP group vs. 14 out of 188 patients (7.5%) in the control group, with an odds ratio (OR) of 0.61 (95% CI 0.23-1.56;  $P = 0.29$ ). The authors concluded that AP is not effective in reducing the incidence of colitis syndrome in patients undergoing colorectal ESD [20].

It seems reasonable not to recommend routine AP for uncomplicated colorectal EMR procedures.

Due to the lack of consolidated data or well-conducted prospective multicenter studies, and given the widespread use of AP in many centers, the decision to use AP in colorectal ESD should be left to the discretion of the operator and anesthetist, in conjunction with the infectious disease specialists in the institution.

### **Device-assisted enteroscopy**

There is no data on the risk of bacteremia associated with device-assisted enteroscopy (double-balloon or spiral enteroscopy).

### **Diagnostic endoscopic ultrasound (EUS)**

The frequency of bacteremia after diagnostic upper EUS is comparable to that of diagnostic upper endoscopy [21].

Prospective studies in patients undergoing endoscopic ultrasound fine-needle aspiration or biopsy (EUS-FNA/B) of solid lesions along the upper gastrointestinal (GI) tract indicate a low prevalence of bacteremia ranging from 4.0% to 5.8%, in most cases without clinical symptoms of infection [22-38].

EUS-FNA/B of a solid rectal and peri-rectal lesion also appears to be associated with a low risk of bacteremia without clinical consequence and infection, estimated at 1% to 2% in studies [32, 39, 40]. In a large prospective study, there was no statistically significant difference in bacteremia between patients who received AP and those who

did not **[21]**. Thus, current recommendations do not advocate for AP before EUS-FNA/B of solid lesions along the upper and lower GI tract **[21, 41]**.

Endoscopic ultrasound fine-needle aspiration (EUS-FNA) of pancreatic cystic lesions (CL) is considered as a relatively safe technique, with a reported low infection risk of 0.44% in a recent meta-analysis **[42]**. The adverse events rate is similar when using a 19-gauge needle (5.84% [95% CI 0.88%-13.64%]) or a 22-gauge needle (2.38% [95% CI 1.38%-3.63%]), and does not seem to be influenced by the number of passes within the pancreatic CL: 2.17% with a single pass (95% CI 1.21%-3.40%) vs. 3.45% with multiple passes (95% CI 1.41%-6.33%) **[42]**.

To reduce the risk of infection after pancreatic CL EUS-FNA, and despite the lack of any prospective randomized controlled studies, current recommendations suggest complete aspiration of the pancreatic CL (in only one pass, where possible), using large caliber suction needles (22 or 19 gauge), and administering AP (usually with fluoroquinolones or beta-lactams) **[21, 41, 43]**. However, this approach is mainly based on historical clinical practice with a low level of scientific evidence. Routine AP has several drawbacks, such as increased procedure cost and the risk of drug resistance **[44, 45]**, and can be associated with potentially severe allergic reactions and secondary infections, with rates ranging from 1.4% to 3.4% in studies **[42, 46, 47]**. Moreover, treatment regimens involving parenteral antibiotic administration before endoscopic procedures or oral treatments after the procedure increase the complexity of the procedure, leading to non-adherence to treatment.

Another important point to underline is the lack of homogeneity in the definition of pancreatic CL infection in the literature **[48-50]** and in current recommendations **[21, 41, 43]**.

In recent years, several studies have questioned the systematic use of AP for pancreatic CL EUS-FNA and queried its effectiveness. In the retrospective comparative trial by Guarner-Argente et al., no protective effect of AP on the incidence of infectious complications after pancreatic CL EUS-FNA/B was observed, and complications remained very low (1.1% in the AP group vs. 0.6% in the non-AP group) **[46]**.

Recently, a Spanish multicenter randomized trial compared the use of AP with ciprofloxacin vs. placebo in 205 patients undergoing pancreatic CL EUS-FNA **[49]**. The infection rate was very low (0.44%), with no significant difference between the two groups in terms of infection (RR 0.87%; 95% CI -0.84%-2.59%), fever (2 patients in each group: 1.78% vs. 1.76%;  $P = 1.00$ ), or other adverse events **[49]**.

In the propensity score-matched retrospective study by Facciorusso et al., there was no significant difference in the rate of infectious complications in patients undergoing pancreatic CL EUS-FNA between the groups with (1.4%) and without (2.2%) AP ( $P = 0.65$ ) **[47]**. A recent meta-analysis including 6 studies (1 randomized and 5 retrospective) and 1,706 patients (of whom 1,038 received AP, mostly with fluoroquinolones) showed no difference between the two groups in terms of infection: 0.77% (8/1,038 cases) in the AP group vs. 1.8% (12/668) in the control group (RR 0.65; 95% CI 0.24-1.78;  $P = 0.40$ ), or in terms of other complications **[51]**.

Very few studies have evaluated the infectious risk associated with “through-the-needle” techniques, such as confocal endomicroscopy and intra-cystic biopsy with the Moray micro-forceps. In the meta-analysis by Facciorusso et al., including 10 studies and 536 patients, only 3 cases (0.6%) of infection occurred after EUS-FNA coupled with exploration of pancreatic CL with the confocal endomicroscopy probe; however, systematic AP had been administered in 6 studies **[52]**.



In a recent propensity score-matched multicenter retrospective study, involving 147 patients with pancreatic CL, Facciorusso et al. evaluated the rate of infectious complications associated with EUS-FNA coupled with intra-cystic biopsy with the Moray micro-forceps in two patient groups, without (49) and with (98) AP **[48]**. Only one case of infection occurred in each group (2% without AP and 1% with AP) ( $P = 0.48$ ) **[48]**. In a retrospective study involving 506 patients with pancreatic CL (IPMN: 45%; serous cystadenoma: 18.8%; and mucinous cystadenoma: 12.8%) undergoing intra-cystic biopsy with the micro-forceps, the rate of infectious complications was 2%, half of which were severe **[34]**. In multivariate analysis, age (RR 1.32, 1.09-2.14;  $P = 0.05$ ), the number of passes (RR 2.17, 1.32-4.34 to RR 3.16, 2.03-6.34 with an increase in the number of passes), complete cyst aspiration (RR 0.56, 0.31-0.95;  $P = 0.02$ ), and the diagnosis of pancreatic intraductal papillary mucinous neoplasm (IPMN) (RR 4.16, 2.27-7.69;  $P < 0.001$ ) were defined as independent predictive factors of complications **[53]**.

The increased risk of infection after mediastinal CL EUS-FNA, supported by numerous case series, is why this procedure is generally contraindicated. AP has not been prospectively studied in this indication **[54]**, but AP is currently recommended by some authors given the morbidity associated with the occurrence of potential mediastinitis **[21, 55-61]**.

The incidence of infectious complications associated with pelvic CL EUS-FNA has not been evaluated **[62]**. Puncture of vestigial cysts in the retrorectal space is generally contraindicated, as it is usually insufficient for diagnosis and can cause infection in the case of a meningocele and tumor dissemination in the case of carcinoma **[63]**. As a rare situation, only a few case series on diagnosis of pelvic CL by EUS-FNA **[64-68]** have been reported, with the occurrence of infectious complications in some cases **[66]**.

Moreover, no infectious complication was recorded in the 20 patients (4%) who underwent pelvic CL EUS-FNA in the study by Levy et al.; however, systematic AP had been administered in 75% of cases **[40]**. Rzouq et al. reported no infectious complications following the puncture of 5 pelvic CL after ciprofloxacin-based AP, starting on the day of sampling for a total of 3 days **[69]**. Two cases of infection (7%), one occurring despite AP, were described by Mohamadnejad et al. **[70]**.

The risk of infection following EUS-FNA/B of ascites or peritoneal nodules in ascites and pleural fluid, despite AP, has been reported in two studies involving a total of 85 patients, estimated at 4% (1/25) and 3% (2/60), respectively **[71-72]**. Three other studies reported no complications in 47 patients who did not receive AP **[73-75]**.

Currently, there is no consensus on the optimal type of AP that should be administered for diagnostic or therapeutic EUS-FNA/B **[21, 41, 43]**.

The reported data show the diversity of AP used in studies, which significantly limits the evaluation of the effectiveness of these different types of AP in reducing the incidence of infection following endoscopic ultrasound procedures.

There is also no consensus on the duration of AP, with some authors administering the treatment only during the procedure, while others continue after the procedure, for a duration ranging from 2 to 5 days in studies. However, no study has evaluated the benefit of continuing AP for a short duration after the procedure. Therefore, there is currently no scientific evidence to recommend short-duration antibiotic treatment after per-procedure AP.

## **Therapeutic EUS**

Currently, there is no data indicating that AP is beneficial in preventing infectious complications after therapeutic EUS. Until data becomes available, a single dose of intravenous antibiotics during a transmural therapeutic procedure is recommended, analogous to protocols in surgery and interventional radiology [76]. Longer administration periods may be necessary in the presence of ascites, in immunocompromised patients, or in patients for whom adequate biliary drainage has not been achieved [76].

Isolated cases of retroperitoneal abscesses following EUS-guided celiac plexus neurolysis have been reported [77-81].

## **b/ High-risk endoscopic procedures**

### **Percutaneous endoscopic gastrostomy**

Percutaneous endoscopic gastrostomy is recognized as a high-risk infectious procedure, occurring in 4.3% to 16% of cases, with pathogens primarily originating in the oro-pharyngeal area. Seven randomized studies against a placebo have been published. A meta-analysis of these trials shows a significant reduction in relative and absolute infection risks when AP is used, by 73% and 17.5%, respectively [82]. The benefit of AP is demonstrated regardless of the patient type. The antibiotics administered in these studies were cephalosporins or amoxicillin-clavulanic acid.

### **Esophageal variceal sclerosis (EVS)**

The risk of bacteremia after EVS ranges from 4% to 56%, with an average of 20% [83]. Two controlled studies using cefuroxime or cefotaxime have shown a significant decrease in the rate of bacteremia, but the reduction in the rate of clinical infection is not clearly evident [84]. However, AP is recommended for all patients (especially frail patients who are often neutropenic and immunocompromised). Esophageal variceal ligation (EVL) is associated with a lower rate of bacteremia, ranging from 1% to 25%, with an average of 9%.

### **EVL during hemorrhagic and non-hemorrhagic episodes**

During a hemorrhagic episode in a patient with cirrhosis, AP leads to a reduction in the infection rate and an improvement in survival [85-87]. A short-duration regimen appears to be sufficient, as shown in a recent randomized study comparing 3 days vs. 7 days of ceftriaxone at 1g/day in terms of re-bleeding and survival [88].

As per the latest European recommendations on portal hypertension (Baveno VII), AP is an integral part of the treatment for patients with cirrhosis experiencing upper gastrointestinal bleeding. AP should be initiated as soon as the patient is admitted, without waiting for diagnostic and therapeutic EGD. The risks of bacterial infection and mortality are very low in patients with Child-Pugh class A cirrhosis, but there is a lack of prospective studies to show that AP should not be administered to this patient subgroup. Individual patient risk characteristics and local antibiotic sensitivity patterns should be considered when choosing the antibiotic. As a first-line approach, 1g of intravenous ceftriaxone every 24 hours should be considered for patients with advanced cirrhosis (strong recommendation, high level of evidence), especially for hospitalized patients due to the high prevalence of quinolone resistance and for patients treated with quinolones for prophylaxis [89].

On the other hand, there is no literature data to recommend systematic AP for EVL outside hemorrhagic episodes.

## Endoscopic retrograde cholangiopancreatography (ERCP)

In a large consecutive prospective study involving 2,769 patients, post-ERCP cholangitis was reported in 0.87% of cases [90]. In a recent retrospective study involving 4,324 patients, independently identified risk factors for post-ERCP cholangitis in unselected patients were hilum obstruction, age  $\geq$  60 years, and a history of ERCP, while complete extraction of bile duct stones was protective [91]. Incomplete biliary drainage (cannulation failure, persistence of stones, unstented intra- or extrahepatic stenosis, and suboptimal clearance at the end of the procedure according to operator judgment) is recognized as the primary risk factor for cholangitis [92-93].

Primary sclerosing cholangitis (PSC) and hilum obstruction, both exposing the patient to incomplete biliary drainage, are also associated with the risk of post-ERCP cholangitis, although no controlled studies are available [92-94]. Ultimately, while AP reduces the risk of bacteremia, as demonstrated in the most recent meta-analysis of 10 randomized trials, it is not associated with a reduction in the risk of cholangitis, septicemia, pancreatitis, or death, thereby limiting its utility [95]. In a large retrospective study involving 4,214 ERCPs, cholangioscopy appears to increase the risk of cholangitis, likely due to the need for bile irrigation (1.0% vs. 0.2%; OR 4.98; 95% CI [1.06-19.67]) [96]. A recent study suggested that bacteremia was specifically linked to cholangioscopy in 13.9% of patients (10/72), based on serial blood samples [97]. Another prospective study, which reported bacteremia and cholangitis rates of 8.8% and 7%, respectively, without AP, found that bacteremia was significantly associated with biopsy procedures and the presence of strictures [98].

ERCP with the placement of a self-expandable metal biliary stent exposes the patient to the risk of acute cholecystitis due to obstruction of the cystic duct, with an incidence rate ranging from 1.9% to 12% [99]. According to two meta-analyses, the fact the stent is covered or uncovered does not seem to have any impact on the incidence rate [100-101]. Cases of cholecystitis after metal stent placement are mainly described in patients with malignant biliary obstruction, likely due to the filling of the gallbladder with non-sterile bile and/or contrast agent during opacification. Gallbladder opacification during ERCP should be avoided to prevent exacerbating this risk.

In its latest 2020 recommendations, the European Society of Gastrointestinal Endoscopy (ESGE) advises against the systematic use of AP before ERCP (strong recommendation, moderate level of evidence). However, AP before ERCP should be considered in the case of pre-interventional doubt about the ability to complete biliary drainage, in severely immunocompromised patients, and during cholangioscopy (weak recommendation, moderate level of evidence). The ESGE also suggests evaluating patients with post-ERCP cholangitis by abdominal ultrasound or computed tomography (CT) and, in the absence of improvement with conservative treatment, considering a repeat ERCP. In the case of a repeat ERCP, it recommends sampling bile for bacteriological examination (weak recommendation, low level of evidence) [102]. While the benefit of AP has not been studied in the case of the placement of a self-expandable metal biliary stent in a gallbladder in situ, AP may still be indicated, as highlighted in the recommendations of the American Society for Gastrointestinal Endoscopy (ASGE) [103].

Currently, there is no data indicating that AP is beneficial in preventing infectious complications after pancreatoscopy. Until data becomes available, the decision for AP administration should be considered by endoscopist and anesthesiologist, accordingly with the institutional protocol.

## **Bariatric procedures (endoscopic sleeve procedure)**

Currently, there is no data indicating that AP is beneficial in preventing infectious complications after endoscopic sleeve procedure. Until data becomes available, the decision for AP administration should be considered by endoscopist and anesthesiologist, accordingly with the institutional protocol.

## **E/ Prescription modalities for AP**

### **a/ Organizational modalities**

As emphasized by the SFAR in its 2018 recommendations<sup>1</sup>, the selected protocols must be written, co-signed by anesthesiologists-intensivists and operators, and validated by the Infection Control Committee (CLIN) and, depending on the internal organization, by the Drug and Sterile Medical Devices Committee or the Anti-infective Agents Committee.

These protocols should be available and may be displayed in pre-anesthetic consultation rooms, operating rooms, post-intervention surveillance rooms, and care units.

The endoscopist and anesthesiologist-intensivist must jointly determine, based on the type of planned intervention, the level of bacterial infectious risk, and the patient's history (allergies, infections, etc.), the necessity of AP.

It is up to each team to decide which physician is responsible for prescribing AP.

AP protocols must be updated regularly, taking into account new scientific data, developments in interventional techniques, and bacterial resistance profiles.

Furthermore, it is recommended to administer AP with a cephalosporin (or its alternatives in the case of allergy, excluding vancomycin) as early as 60 minutes before and no later than the start of the interventional procedure, in order to reduce the incidence of surgical site infection. If vancomycin is used for AP, experts suggest starting intravenous administration over 60 minutes in non-obese patients as early as 60 minutes and no later than 30 minutes before the start of the interventional procedure, in order to reduce the incidence of surgical site infection. There should be a gap of 5 to 10 minutes between the injection of the anesthetic induction products and the AP, in order to be able to determine - in the case of an allergic reaction - the contribution of each in the occurrence of the complication. The operator must ensure that AP has been properly prescribed, especially by checking the "checklist".

The spectrum of action of the antibiotic should include the bacteria most frequently involved in the infection of the interventional site. In digestive endoscopy, the antibiotic agent should thus be active against *E. coli* and other Enterobacteriaceae, methicillin-sensitive *Staphylococcus aureus*, and, in certain circumstances, anaerobic bacteria. It is necessary to check for any allergic history before administration.

### **b/ Administration schemes (see Table 2)**


The commonly accepted protocol is 2g of intravenous cefoxitin as early as 60 minutes before and no later than the start of the interventional procedure. In the case of

<sup>1</sup> <https://sfar.org/wp-content/uploads/2018/07/Antibioprophylaxie-RFE-mise-a-jour-2018.pdf>

penicillin allergy, a 30-minute infusion of gentamicin at a dose of 6-7mg/kg/day of adjusted weight combined with intravenous metronidazole at a dose of 1,000mg could be an alternative.

However, concerning ERCP, since clinical scenarios such as failed cannulation or remnant stones cannot be anticipated prior to the procedure, to decrease the risk of cholangitis, AP is initiated during or immediately at the end of the procedure in cases where prevention before the ERCP was not initially required.

The protocols below, taking into account certain specific situations to adapt AP to specific bacterial infectious risks, reiterate, for clarity, the proposals made by the SFAR in its 2018 recommendations, drawn up jointly with the SPLIF and updated in 2023 in collaboration with the recommendations committee of the French Society of Digestive Endoscopy (SFED). Given the low level of evidence in some indications, administration schemes have been retained by assimilation and expert opinion, and will need to be updated in light of evolving knowledge.





## SFED recommendations

- **Diagnostic endoscopy with or without biopsy:** No AP (strong recommendation, low level of evidence).

- **ERCP:** No systematic AP (strong recommendation, moderate level of evidence).

- **ERCP with suspected incomplete biliary drainage\*, or in immunocompromised patients, or in the case of cholangioscopy:** Administration of cefoxitin (2g, slow IV). In the case of allergy, administration of gentamicin (6-7mg/kg/day) combined with metronidazole (1g, single-dose infusion), to be completed ideally as early as 60 minutes before and no later than the start of the interventional procedure (weak recommendation, moderate level of evidence).

Since clinical scenarios such as failed cannulation or remnant stones cannot be anticipated always prior to the procedure, to decrease the risk of cholangitis, AP is initiated during or immediately at the end of the procedure in cases where prevention before the ERCP was not initially required (week recommendation, moderate level of evidence),

\* **Criteria for incomplete drainage:** cannulation failure, persistence of stones or microlithiasis especially at the end of lithotripsy, unstented intra- or extrahepatic stenosis, and suboptimal clearance at the end of the procedure according to operator judgment.

**Pancreatoscopy:** The decision for AP administration should be considered by endoscopist and anesthesiologist, accordingly with the institutional protocol (week recommendation, no evidence).

- **PEG:** Administration of cefazoline (2g, slow IV). In the case of allergy, administration of vancomycin (20mg/kg IBW, slow IV) (strong recommendation, high level of evidence).

If vancomycin is used for AP, experts suggest starting intravenous administration over 60 minutes in non-obese patients as early as 60 minutes and no later than 30 minutes before the surgical incision or the start of the interventional procedure, in order to reduce the incidence of surgical site infection (expert opinion).

- **Sclerotherapy of esophageal varices:** No systematic AP, as sclerotherapy of esophageal varices outside an hemorrhagic episode is no longer indicated (strong recommendation, low level of evidence).

- **LVO during a hemorrhagic episode:** Intravenous administration of ceftriaxone (1-2g/24h) for patients with advanced cirrhosis (1b; A), hospitalized patients due to the high prevalence of quinolone resistance, and patients treated with quinolone prophylaxis, or administration of fluoroquinolone for other patients (oral norfloxacin, 400mg twice daily for 7 days) (strong recommendation, high level of evidence).

- **LVO outside a hemorrhagic episode:** No systematic AP (strong recommendation, high level of evidence).

- **Peritoneal dialysis:** Administration 30 minutes before antibiotic therapy with ampicillin (1g) and a single dose of aminoglycoside. Moreover, complete drainage of all peritoneal dialysate before the endoscopic procedure should be performed according to the recommendations of the International Society for Peritoneal Dialysis (ISPD) [9] (strong recommendation, low level of evidence).

- **EUS-FNA/B of solid lesions,** along the gastrointestinal and biliary-pancreatic tract or lymph nodes: No systematic AP (strong recommendation, low level of evidence).

- **EUS-FNA of pancreatic cystic lesions**, including “through the needle” techniques (confocal endomicroscopy, biopsies with the Moray micro-forceps): No solid scientific evidence to suggest systematic AP. The decision is left to the discretion of the practitioner and should be discussed based on the risk factors associated with the endoscopic procedure (intra-cystic bleeding, incomplete aspiration of the cystic lesion after puncture) and/or the patient (immunosuppression, neutropenia, and/or high risk of infective endocarditis) (weak recommendation, low level of evidence).

- **EUS-FNA of mediastinal or peri-rectal cyst**: Due to a high risk of morbidity, these procedures should be avoided (strong recommendation, low level of evidence).

- **EUS-FNA/B of ascites or peritoneal nodules in ascites and pleural fluid**: Systematic AP (weak recommendation, low level of evidence).

- **Endoscopic ultrasound with cystogastrostomy/cystoduodenostomy**; biliary-digestive or wirsungo-gastric anastomosis, cholecystostomy, gastrojejunal anastomosis, EDGE, tissue destruction by EUS-guided radiofrequency, EUS-guided celiac plexus neurolysis, drainage of pelvic collections: Systematic AP (weak recommendation, low level of evidence).

- **Endoscopic dilation**: No AP (strong recommendation, low level of evidence).

- **Placement of biliary-digestive stents (excluding incomplete biliary drainage, PSC, or tumor obstruction with the gallbladder in situ)**: No AP (strong recommendation, low level of evidence).

- **Esophagogastric and rectal radiofrequency**: No AP (strong recommendation, low level of evidence).

- **EMR (esophagogastric or colorectal)**: No AP (strong recommendation, low level of evidence). In the case of therapeutic breach, non-prophylactic antibiotic therapy should be discussed, on a case-by-case basis and according to the circumstances (weak recommendation, low level of evidence).

- **Submucosal dissection (esophago-gastric or colorectal)**: The decision for AP administration should be considered by endoscopist and anesthesiologist, accordingly with the institutional protocol. In the case of therapeutic breach, non-prophylactic antibiotic therapy should be initiated (weak recommendation, moderate level of evidence).

- **Endoscopic sleeve procedure**: The decision for AP administration should be considered by endoscopist and anesthesiologist, accordingly with the institutional protocol (weak recommendation, no evidence).

*Competing interests in relation to the guidelines:* None declared.

*Other competing interest:*

David Karsenti, MD: Consultant for OLYMPUS, COVIDEN and NORGINE; Support for attending meetings from ALFASIGMA, COOK and FUJIFILM

Rodica Gincul, MD: Consultant for OLYMPUS; Honoraria for lectures from OLYMPUS; Support for attending meetings from CELTRION, ABBVIE

Arthur Belle, MD: Consultant for BOSTON SCIENTIFIC; Support for attending meeting from MAYOLI

Geoffroy Vanbiervliet, MD-PhD: Consultant for BOSTON SCIENTIFIC and AMBU; Honoraria for lectures, presentations and speeches from PENTAX, FUJIFILM, TILLOTS and NORGINE

Olivier Gronier, MD: Support for attending meetings from Dr FALK

## Bibliography:

1. **Wilson W**, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. **Circulation** **2007**; 116: 1736-1754
2. **Dumonceau JM**, Hassan C, Riphaut A, Ponchon T. European Society of Gastrointestinal Endoscopy (ESGE) Guideline Development Policy. **Endoscopy** **2012**; 44: 626-629
3. **Habib G**, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009). The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). **European Heart Journal** **2009**; 30: 2369-2413
4. **Martin C**, Auboyer C, Boisson M, et al. Antibioprophylaxis in surgery and interventional medicine (adult patients). Update 2017. *Anaesth Crit Care Pain Med* 2019;38:549-562
5. **Zimmerli W**, Trampuz A, Ochsner PE. Prosthetic joint infections. **N Engl J Med** **2004**; 351: 1645-1654
6. **Khashab MA**, Chithadi KV, Acosta RD, et al. Antibiotic prophylaxis for GI endoscopy. **Gastrointestinal Endoscopy** **2015**; 81: 81-89
7. **Bianco JA**, Pepe MS, Higano C, et al. Prevalence of clinically relevant bacteremia after upper gastrointestinal endoscopy in bone marrow transplant recipients. **Am J Med** **1990**; 89: 134-136
8. **Piraino B**, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. **Perit Dial Int** **2005**; 25: 107-131
9. **Piraino B**, Bernardini J, Brown E, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. **Perit Dial Int.** **2011**; 31: 614-630
10. **ASGE Standards of Practice Committee; Khashab MA**, Chithadi KV et al. Antibiotic prophylaxis for GI endoscopy. **Gastrointest Endosc** **2015**; 81: 81-89
11. **Gweon TG**, Jung SH, Kim SW, et al. Risk factors for peritonitis in patients on continuous ambulatory peritoneal dialysis who undergo colonoscopy: a retrospective multicentre study. **BMC Gastroenterol** **2019**; 19: 175
12. **Kim JS**, Jung E, Kang SH, J, et al. Safety of Endoscopy in Peritoneal Dialysis Patients. *Clin Transl Gastroenterol* 2021; 12: e00379
13. **O'Connor HJ**, Hamilton I, Lincoln C, et al. Bacteremia with upper gastrointestinal endoscopy - a reappraisal. **Endoscopy** **1983**; 15: 21-23
14. **Liu Y**, Chen Y, Shu X, et al. Prophylactic antibiotics may be unnecessary in gastric endoscopic submucosal dissection due to the low incidence of bacteremia. **Surg Endosc** **2020**; 34: 3788-3794

15. **Kawata N**, Tanaka M, Kakushima N, et al. The low incidence of bacteremia after esophageal endoscopic submucosal dissection (ESD) obviates the need for prophylactic antibiotics in esophageal ESD. **Surg Endosc.** **2016**; 30: 5084-5090
16. **Maselli R**, Oliva A, Badalamenti M, et al. Single-dose versus short-course prophylactic antibiotics for peroral endoscopic myotomy: a randomized controlled trial. **Gastrointest Endosc** **2021**; 10: S0016-5107(21)01418-8
17. **Hastier-De Chelle A**, Onana-Ndong P, Olivier R, et al. Impact of antibiotic prophylaxis and conditioning modalities in per-oral endoscopic myotomy for esophageal motor disorders. *Scand J Gastroenterol* **2022**; 57: 1522-1530.
18. **Chun YJ**, Yoon NR, Park JM, et al. Prospective assessment of risk of bacteremia following colorectal stent placement. **Dig Dis Sci** **2012**; 57: 1045-1049
19. **La Regina D**, Mongelli F, Fasoli A, et al. Clinical Adverse Events after Endoscopic Resection for Colorectal Lesions: A Meta-Analysis on the Antibiotic Prophylaxis. **Dig Dis** **2020**; 38: 15-22
20. **Shichijo S**, Takeuchi Y, Shimodate Y, et al. Performance of perioperative antibiotics against postendoscopic submucosal dissection coagulation syndrome: a multicenter randomized controlled trial. **Gastrointest Endosc** **2022**; 95: 349-359
21. **ASGE Standards of Practice Committee**; Khashab MA, Chithadi KV, Acosta RD, et al. Antibiotic prophylaxis for GI endoscopy. **Gastrointest Endosc** **2015**; 81: 81-89
22. **Bhutani MS**, Hawes RH, Baron PL, et al. Endoscopic ultrasound guided fine needle aspiration of malignant pancreatic lesions. **Endoscopy** **1997**; 29: 854-858
23. **Chang KJ**, Nguyen P, Erickson RA, et al. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. **Gastrointest Endosc** **1997**; 45: 387-393
24. **Barawi M**, Gottlieb K, Cunha B, et al. A prospective evaluation of the incidence of bacteremia associated with EUS-guided fine-needle aspiration. **Gastrointest Endosc** **2001**; 53: 189-192
25. **Levy MJ**, Norton ID, Wiersema MJ, et al. Prospective risk assessment of bacteremia and other infectious complications in patients undergoing EUS-guided FNA. **Gastrointest Endosc** **2003**; 57: 672-678
26. **Janssen J**, König K, Knop-Hammad V, et al. Frequency of bacteremia after linear EUS of the upper GI tract with and without FNA. **Gastrointest Endosc** **2004**; 59: 339-344
27. **Eloubeidi MA**, Tamhane A, Varadarajulu S, et al., Frequency of major complications after EUS-guided FNA of solid pancreatic masses: a prospective evaluation. **Gastrointest Endosc** **2006**; 63: 622-629
28. **O'Toole D**, Palazzo L, Arotçarena R, et al. Assessment of complications of EUS-guided fine-needle aspiration. **Gastrointest Endosc** **2001**; 53: 470-474



29. **Eloubeidi MA**, Tamhane A. Prospective assessment of diagnostic utility and complications of endoscopic ultrasound-guided fine needle aspiration. Results from a newly developed academic endoscopic ultrasound program. **Dig Dis** 2008; 26: 356-363
30. **Al-Haddad M**, Wallace MB, Woodward TA, et al. The safety of fine-needle aspiration guided by endoscopic ultrasound: a prospective study. **Endoscopy** 2008; 40: 204-208
31. **Carrara S**, Arcidiacono PG, Mezzi G, et al. Pancreatic endoscopic ultrasound-guided fine needle aspiration: complication rate and clinical course in a single centre. **Dig Liver Dis** 2010; 42: 520-523
32. **Wang KX**, Ben QW, Jin ZD, et al. Assessment of morbidity and mortality associated with EUS-guided FNA: a systematic review. **Gastrointest Endosc** 2011; 73: 283-290
33. **Jenssen C**, Alvarez-Sánchez MV, Napoléon B, et al. Diagnostic endoscopic ultrasonography: assessment of safety and prevention of complications. **World J Gastroenterol** 2012; 18: 4659-4676
34. **Polkowski M**, Larghi A, Weynand B et al. Learning, techniques, and complications of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline. **Endoscopy** 2012; 44: 190-206
35. **Katanuma A**, Maguchi H, Yane K, et al. Factors predictive of adverse events associated with endoscopic ultrasound-guided fine needle aspiration of pancreatic solid lesions. **Dig Dis Sci** 2013; 58: 2093-1099
36. **Banafea O**, Mghanga FP, Zhao J, et al. Endoscopic ultrasonography with fine-needle aspiration for histological diagnosis of solid pancreatic masses: a meta-analysis of diagnostic accuracy studies. **BMC Gastroenterol** 2016; 16: 108
37. **Rodriguez-D'Jesus A**, Mghanga FP, Zhao J, et al. Adverse events of EUS-guided FNA of pancreatic cystic and solid lesions by using the lexicon proposed in an ASGE workshop: a prospective and comparative study. **Gastrointest Endosc** 2016; 83: 780-784
38. **Yoshinaga S**, Itoi T, Yamao K, et al. Safety and efficacy of endoscopic ultrasound-guided fine needle aspiration for pancreatic masses: A prospective multicenter study. **Dig Endosc** 2020; 32: 114-126
39. **Levy MJ**, et al. Prospective study of bacteremia and complications With EUS FNA of rectal and perirectal lesions. **Clin Gastroenterol Hepatol** 2007; 5: 684-689
40. **Levy MJ**, Norton ID, Clain JE, et al. Prospective evaluation of adverse events following lower gastrointestinal tract EUS FNA. **Am J Gastroenterol**, 2014; 109: 676-685
41. **Polkowski M**, Jenssen C, Kaye P, et al. Technical aspects of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline - March 2017. **Endoscopy** 2017; 49: 989-1006
42. **Zhu H**, Jiang F, Zhu J, et al. Assessment of morbidity and mortality associated with endoscopic ultrasound-guided fine-needle aspiration for pancreatic cystic lesions: A systematic review and meta-analysis. **Dig Endosc** 2017; 29: 667-675

43. Allison MC, Sandoe JA, Tighe R, et al. Antibiotic prophylaxis in gastrointestinal endoscopy. **Gut** 2009; 58: 869-680
44. Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. **Lancet Infect Dis** 2019; 19: 56-66
45. Haenni M, Dagot C, Chesneau O, et al. Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes. **Environ Int** 2022; 159: 107047.
46. Guarner-Argente C, Shah P, Buchner A, et al. Use of antimicrobials for EUS-guided FNA of pancreatic cysts: a retrospective, comparative analysis. **Gastrointest Endosc** 2011; 74: 81-86.
47. Facciorusso A, Buccino VR, Turco A, et al. Antibiotics Do Not Decrease the Rate of Infection After Endoscopic Ultrasound Fine-Needle Aspiration of Pancreatic Cysts. **Dig Dis Sci** 2019; 64: 2308-2315.
48. Facciorusso A, Arevalo-Mora M, Conti Bellocchi MC, et al. Impact of Antibiotic Prophylaxis on Infection Rate after Endoscopic Ultrasound Through-the-Needle Biopsy of Pancreatic Cysts: A Propensity Score-Matched Study. **Diagnostics (Basel)** 2022; 12: 211
49. Colan-Hernandez J, Sendino O, Loras C, et al. Antibiotic Prophylaxis Is Not Required for Endoscopic Ultrasonography-Guided Fine-Needle Aspiration of Pancreatic Cystic Lesions, Based on a Randomized Trial. **Gastroenterology** 2020; 158: 1642-1649 e1
50. Klein A, Qi R, Nagubandi S, et al. Single-dose intra-procedural ceftriaxone during endoscopic ultrasound fine-needle aspiration of pancreatic cysts is safe and effective: results from a single tertiary center. **Ann Gastroenterol** 2017; 30: 237-241
51. Facciorusso A, Mohan BP, Tacelli M, et al. Use of antibiotic prophylaxis is not needed for endoscopic ultrasound-guided fine-needle aspiration of pancreatic cysts: a meta-analysis. **Expert Rev Gastroenterol Hepatol** 2020; 14: 999-1005
52. Facciorusso A, Buccino VR, Sacco R. Needle-based confocal laser endomicroscopy in pancreatic cysts: a meta-analysis. **Eur J Gastroenterol Hepatol** 2020; 32: 1084-1090
53. Facciorusso A, Kovacevic B, Yang D, et al. Predictors of Adverse Events after Endoscopic Ultrasound through-the-Needle Biopsy of Pancreatic Cysts: A Recursive Partitioning Analysis. **Endoscopy** 2022; 54: 1158-1168.
54. Fazel A, Moezardalan K, Varadarajulu S, et al. The utility and the safety of EUS-guided FNA in the evaluation of duplication cysts. **Gastrointest Endosc**, 2005; 62: 575-580
55. Diehl DL, Cheruvattath R, Facktor MA, et al. Infection after endoscopic ultrasound-guided aspiration of mediastinal cysts. **Interact Cardiovasc Thorac Surg** 2010; 10: 338-340
56. Annema JT, Veselić M, Versteegh MI, et al. Mediastinitis caused by EUS-FNA of a bronchogenic cyst. **Endoscopy** 2003; 35: 791-793

57. **Wildi SM**, Hoda RS, Fickling W, et al. Diagnosis of benign cysts of the mediastinum: the role and risks of EUS and FNA. **Gastrointest Endosc** 2003; 58: 362-368
58. **Ryan AG**, Zamvar V, and Roberts SA. Iatrogenic candidal infection of a mediastinal foregut cyst following endoscopic ultrasound-guided fine-needle aspiration. **Endoscopy** 2002; 34: 838-839
59. **Westerterp M**, van den Berg JG, van Lanschot JJ, et al. Intramural bronchogenic cysts mimicking solid tumors. *Endoscopy*, 2004; 36: 1119-1122
60. **Bournet B**, Miguères I, Delacroix M, et al. Early morbidity of endoscopic ultrasound: 13 years' experience at a referral center. **Endoscopy** 2006; 38: 349-354
61. **ASGE STANDARDS OF PRACTICE COMMITTEE; Banerjee S**, Shen B, Baron TH, et al. Antibiotic prophylaxis for GI endoscopy. **Gastrointest Endosc** 2008; 67: 791-798
62. **Han C**, Lin R, Liu J, Hou X, et al. Endoscopic Ultrasonography-Guided Biopsy for Differentiation of Benign and Malignant Pelvic Lesions: A Systematic Review and Meta-Analysis. **Dig Dis Sci** 2015; 60: 3771-3781
63. **Grandjean JP**, Manton GA, Guinier D, et al. Vestigial retrorectal cystic tumors in adults: a review of 30 cases. **Gastroenterol Clin Biol** 2008; 32: 769-778
64. **Young NA**, Neeson T, Bernal D, et al. Retrorectal cystic hamartoma diagnosed by fine-needle aspiration biopsy. **Diagn Cytopathol** 1990; 6: 359-363
65. **Rathinamanickam H**, Pawa S. A Tailgut Cyst Diagnosed by Endoscopic Ultrasound-Guided Fine-Needle Aspiration. **ACG Case Rep J** 2015; 3: 33-35
66. **Hall DA**, Pu RT, and Pang Y. Diagnosis of foregut and tailgut cysts by endosonographically guided fine-needle aspiration. **Diagn Cytopathol** 2007; 35: 43-46
67. **Pinto-Marques P**, Damião-Ferreira J, Mendonça E, et al. Unusual cause of CA 19.9 elevation diagnosed by endoscopic ultrasound-guided fine needle aspiration: a retrorectal tailgut cyst. **Endoscopy** 2012; 44 Suppl 2 UCTN: E248-9
68. **Siddiqui FA**, Chopra R, and Al-Marzooq Y. Fine needle aspiration cytology diagnosis of tailgut cyst: a rare entity. **Acta Cytol** 2014; 58: 217-220
69. **Rzouq F**, Brown J, Fan F, et al. The utility of lower endoscopic ultrasound-guided fine needle aspiration for the diagnosis of benign and malignant pelvic diseases. **J Clin Gastroenterol** 2014; 48: 127-130
70. **Mohamadnejad M**, Al-Haddad MA, Sherman S, et al. Utility of EUS-guided biopsy of extramural pelvic masses. **Gastrointest Endosc** 2012; 75: 146-151
71. **Kaushik N**, Khalid A, Brody D, McGrath K. EUS-guided paracentesis for the diagnosis of malignant ascites. **Gastrointest Endosc**, 2006; 64: 908-913
72. **DeWitt J**, LeBlanc J, McHenry L, et al. Endoscopic ultrasound-guided fine-needle aspiration of ascites. *Clin Gastroenterol Hepatol* 2007; 5: 609-615
73. **Peter S**, Eltoun I, and Eloubeidi MA. EUS-guided FNA of peritoneal carcinomatosis in patients with unknown primary malignancy. **Gastrointest Endosc** 2009; 70: 1266-1270

74. **Nguyen PT**, Chang KJ. EUS in the detection of ascites and EUS-guided paracentesis. **Gastrointest Endosc** **2001**; 54: 336-339
75. **Rana SS**, Bhasin DK, Srinivasan R, et al. Endoscopic ultrasound-guided fine needle aspiration of peritoneal nodules in patients with ascites of unknown cause. **Endoscopy** **2011**; 43: 1010-1013
76. **van Wanrooij RLJ**, Bronswijk M, Kunda R, et al. Therapeutic endoscopic ultrasound: European Society of Gastrointestinal Endoscopy (ESGE) Technical Review. **Endoscopy** **2022**; 54: 310-332
77. **Gress F**, Schmitt C, Sherman S, et al. Endoscopic ultrasound-guided celiac plexus block for managing abdominal pain associated with chronic pancreatitis: a prospective single center experience. **Am J Gastroenterol** **2001**; 96: 409-416
78. **Hoffman BJ**. EUS-guided celiac plexus block/neurolysis. **Gastrointest Endosc**, **2002**; 56(4 Suppl): S26-28
79. **O'Toole TM**, and Schmulewitz N. Complication rates of EUS-guided celiac plexus blockade and neurolysis: results of a large case series. **Endoscopy** **2009**; 41: 593-597
80. **Puli SR**, Reddy JB, Bechtold ML, et al. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain: a meta-analysis and systematic review. **Dig Dis Sci**, **2009**; 54: 2330-2337
81. **Fabbri C**, Luigiano C, Lisotti A, et al. Endoscopic ultrasound-guided treatments: are we getting evidence based--a systematic review. **World J Gastroenterol** **2014**; 20: 8424-8448
82. **Sharma VK**, Howden CW. Meta-analysis of randomized controlled trials of antibiotic prophylaxis before percutaneous endoscopic gastrostomy. **Am J Gastroenterol** **2000**; 95: 3133-3136
83. **Schembre D**, Bjorkman DJ. Review article: endoscopy related infections. **Aliment Pharmacol Ther** **1993**; 7: 347-355
84. **American Society for Gastrointestinal Endoscopy**. Infection control during gastrointestinal endoscopy. **Gastrointest Endosc** **1999**; 49: 836-841
85. **Thevenot T**, Degand T, Grelat N, et al. A French national survey on the use of antibiotic prophylaxis in cirrhotic patients. **Liver International** **2013**; 33: 389-397
86. **Bernard B**, Grange JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta- analysis. **Hepatology** **1999**; 29: 1655-1661
87. **Goulis J**, Armonis A, Patch D, et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. **Hepatology** **1998**; 2: 1207-1212
88. **Lee TH**, Huang CT, Lin CC, et al. Similar rebleeding rate in 3-day and 7-day intravenous ceftriaxone prophylaxis for patients with acute variceal bleeding. **J Formos Med Assoc** **2016**; 115: 547-552



89. **de Franchis R**, Bosch J, Garcia-Tsao G, et al; Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. **J Hepatol** **2022**; 76: 959-974
90. **Loperfido S**, Angelini G, Benedetti G. et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. **Gastrointest Endosc** **1998**; 48: 1-10
91. **Chen M**, Wang L, Wang Y. et al. Risk factor analysis of post-ERCP cholangitis: A single-center experience. **Hepatobiliary Pancreat Dis Int HBPD INT** **2018**; 17: 55-58
92. **Lee JG**, Lee CE. Infection after ERCP, and antibiotic prophylaxis: a sequential quality-improvement approach over 11 years. **Gastrointest Endosc** **2008**; 67: 476-477
93. **Olsson G**, Enochsson L, Swahn F, Andersson B. Antibiotic prophylaxis in ERCP with failed cannulation. **Scand J Gastroenterol** **2021**; 56: 336-341
94. **Navaneethan U**, Jegadeesan R, Nayak S. et al. ERCP-related adverse events in patients with primary sclerosing cholangitis. **Gastrointest Endosc** **2015**; 81: 410-419
95. **Merchan MFS**, de Moura DTH, de Oliveira GHP, et al. Antibiotic prophylaxis to prevent complications in endoscopic retrograde cholangiopancreatography: A systematic review and meta-analysis of randomized controlled trials. **World J Gastrointest Endosc** **2022**; 14: 718-730
96. **Sethi A**, Chen YK, Austin GL. et al. ERCP with cholangiopancreatography may be associated with higher rates of complications than ERCP alone: a single-center experience. **Gastrointest Endosc** **2011**; 73: 251-256
97. **Thosani N**, Zubarik RS, Kochar R. et al. Prospective evaluation of bacteremia rates and infectious complications among patients undergoing single-operator choledochoscopy during ERCP. **Endoscopy** **2016**;48: 424-431
98. **Othman MO**, Guerrero R, Elhanafi S. et al. A prospective study of the risk of bacteremia in directed cholangioscopic examination of the common bile duct. **Gastrointest Endosc** **2016**; 83: 151-157
99. **Saxena P**, Singh VK, Lennon AM, et al. Endoscopic management of acute cholecystitis after metal stent placement in patients with malignant biliary obstruction: a case series. **Gastrointest Endosc** **2013**; 78: 175-178
100. **Saleem A**, Leggett CL, Murad MH, et al. Meta-analysis of randomized trials comparing the patency of covered and uncovered selfexpandable metal stents for palliation of distal malignant bile duct obstruction. **Gastrointest Endosc** **2011**;74:321-7, e1-3
101. **Almadi MA**, Barkun AN, Martel M. No benefit of covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction: a meta-analysis. **Clin Gastroenterol Hepatol** **2013**; 11: 27-37, e1
102. **Dumonceau JM**, Kapral C, Aabakken L, et al. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. **Endoscopy** **2020**; 52: 127-149



103. ASGE Standards of Practice Committee, Chandrasekhara V, Khashab MA, et al. Adverse events associated with ERCP. **Gastrointest Endosc** 2017; 85: 32-47



This article is protected by copyright. All rights reserved.

Accepted Manuscript

**Table1. Classification of bacterial infectious risk levels for endoscopic procedures**

| Low-risk endoscopy   | High-risk endoscopy   |
|--|---|
| <ul style="list-style-type: none"><li>• Diagnostic endoscopy with or without biopsy</li><li>• ERCP without suspected incomplete drainage</li><li>• Diagnostic EUS-FNA/B (excluding mediastinal or pelvic cystic lesions, ascites, peritoneal nodules in ascites, pleural fluid)</li><li>• Endoscopic dilation</li><li>• Placement of digestive stent (excluding incomplete biliary drainage)</li><li>• Esophagogastric and rectal radiofrequency</li><li>• Endoscopic mucosal resection or submucosal dissection</li></ul> | <ul style="list-style-type: none"><li>• Colonoscopy in a peritoneal dialysis patient, in combination with the aspiration of dialysate before the procedure</li><li>• ERCP with suspected incomplete drainage</li><li>• PEG and jejunostomy</li><li>• Endoscopy in peritoneal dialysis patients</li><li>• Endoscopic ultrasound with biliary-digestive or cysto-gastrostomy anastomosis</li><li>• EUS-FNA/B of mediastinal or pelvic cystic lesions, ascites, peritoneal nodules in ascites, pleural fluid</li></ul> |

ERCP = Endoscopic retrograde cholangiopancreatography; EUS-FNA/B = Endoscopic ultrasound fine-needle aspiration or biopsy; PEG = Percutaneous endoscopic gastrostomy.

**Table 2. Antibiotic prophylaxis in digestive endoscopy (Expert opinion)**

| Endoscopic procedure  | Administration modalities<br>(products, initial dose, dosage and duration)  |
|---|---|
| Low-risk endoscopy  | No AP   |
| <ul style="list-style-type: none"> <li>- ERCP with suspected incomplete drainage*</li> <li>- EUS-FNA/B of ascites, peritoneal nodules in ascites or pleural fluid</li> <li>- Endoscopic ultrasonography with biliary-digestive anastomosis</li> <li>- Cystogastrostomy</li> </ul> | <ul style="list-style-type: none"> <li>- Administration of cefoxitin (2g, slow IV, single dose)</li> <li>- In the case of allergy, administration of gentamicin 6-7mg/kg/day combined with metronidazole (1000mg, slow IV, single dose)</li> <li>- To be completed ideally 60 minutes before and no later than the start of the intervention</li> </ul> |
| PEG   | <ul style="list-style-type: none"> <li>- Administration of cefazolin (2g, slow IV, single dose)</li> <li>- In the case of allergy, administration of vancomycin (20mg/kg, slow IV)</li> </ul>   |
| Peritoneal dialysis   | <ul style="list-style-type: none"> <li>- Administration of AP 30 minutes before the procedure, including ampicillin (1g) and a single dose of aminoglycoside</li> <li>- Additionally, complete drainage of all peritoneal dialysate before the endoscopic procedure should be performed according to the recommendations of the ISPD</li> </ul>         |

\* Incomplete biliary drainage = cannulation failure, persistence of stones, unstented intra- or extrahepatic stenosis, and suboptimal clearance at the end of the procedure according to operator judgment.  
 AP = Antibiotic prophylaxis; ERCP = Endoscopic retrograde cholangiopancreatography; EUS-FNA/B = Endoscopic ultrasound fine-needle aspiration or biopsy; PEG = Percutaneous endoscopic gastrostomy; IV = Intravenous; ISPD = International Society for Peritoneal Dialysis.